What Are Analysts and Indicators Saying About Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO) saw an uptrend of 11.04% in the recent trading with $13.38 being its most recent. The current price level -23.19% lower than the highest price of $17.42 marked by the stock while trading over the past 52-weeks, whereas it is 239.96% higher than the lowest price of $3.94 the company dropped to over past 52-weeks. The latest news story on ALXO appeared in (Zacks) under the title “ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study”.

Squeezing the time span to 30 day period shows us the stock is currently trading -2.41% below one month high and is +27.55% above of the lowest during that time. Looking into the simple moving average, Alx Oncology Holdings Inc (ALXO)’s stock stands at a SMA-50 of $13.66 while that of 5-day is reading $12.43.

Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ALXO’s SMA-200 as of now is $9.66.

Do analysts rate it as a buy, sell or hold?

Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.29 for the stock.

Alx Oncology Holdings Inc Earnings – What Happened With ALXO

Coming around sales and income figures on ALXO Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Alx Oncology Holdings Inc (ALXO) last released financial results for the quarter that ended 12/30/2023, posting a surprise factor of -10.70% for net revenue.

ALXO – Alx Oncology Holdings Inc Stock Earnings Estimates

The perspective of Alx Oncology Holdings Inc (NASDAQ:ALXO)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.84 for stock’s EPS in the current quarter. 6 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.93.

Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 49.95 million. ALXO does have institutional investors; and they hold 57.80% of the stock.

Alx Oncology Holdings Inc – Insider Activity and Holdings

As on Jun 29, 2023, venBio Partners LLC was the top most holder in Alx Oncology Holdings Inc (NASDAQ:ALXO) with an ownership of 9.7 million shares of the company or 23.57% of the stake worth $72.85 million. The filing also reveals FMR, LLC as the second largest holder in the company with a control over 14.90% of the outstanding shares. Its stake is worth $46.04 million for having 6.13 million shares in hand.

Vivo Capital, LLC also came holding a key position in the company during the recent quarter and it now holds 10.25% of the outstanding shares. With this there are now 145 institutions which have possession in ALXO’s shares.

Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.29 for the stock.

The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Alx Oncology Holdings Inc has a debt to equity ratio of 0.09.

Technical Analysis of Alx Oncology Holdings Inc (NASDAQ:ALXO) stock

To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Alx Oncology Holdings Inc (ALXO), we notice that the stock’s 20-day average volume is at 484,440 shares. Medium term indicators at an average of 50% are spotting the stock at Buy with its 50-day average volume of 440,790 shares. And to end, ALXO’s 100-day average volume is 464,633 shares with 100% of the long-term indicators pointing towards Buy for the stock.